MetaphysicalCells: Marina’s Newsletter

Share this post
AI Drug Development Startups
marinatalamanou.substack.com

AI Drug Development Startups

From discovery, preclinical and clinical phase, to drug researching mechanisms and drug repurposing during drug development of natural compounds (i.e. psychedelics), using AI

Marina T Alamanou
Jan 22, 2021
  • Edit post
  • Unpin from home page
  • Exclude from Top
1
Share this post
AI Drug Development Startups
marinatalamanou.substack.com

This blog is dedicated to AI startups during drug development, from discovery, preclinical and clinical phase, to drug researching mechanisms and drug repurposing during drug development of natural compounds (i.e. psychedelics) using AI.

Drug development starts always with screening different molecules and testing them on hundreds of different types of human cells (200 different types of human cells) expressing hundreds of different types of receptors and other proteins, not to mention that every human is different and human cells still evolve.

Considerations on the number of possible molecules to screen has led to the concept of the “chemical space” (known and unknown) to describe the ensemble of all organic molecules to be considered when searching for new drugs.

Whereas the known chemical space including public databases and corporate collections probably contains 100 million molecules, it has been estimated that the unknown virtual chemical space might contain as many as 10⁶⁰ (novemdecillion) compounds when considering only basic structural rules, or a more modest 10²⁰–10²⁴ molecules if combination of known fragments are considered. In comparison, the number of sand grains on Earth is about 7.5 x 10¹⁸. These estimations suggest that this entire chemical space is far too large for an exhaustive enumeration, even using today’s computers. One is therefore left with a partial, targeted enumeration as the only option to produce molecules for virtual screening.

In particular, this review of 2020 “Review on natural products databases: where to find data in 2020” is a complete overview of various databases and collections of natural products (NP) that can be used during drug discovery (over 120 different NP databases and collections published and re-used since 2000 and 98 of them are still somehow accessible and only 50 are open access).

Keep in mind that for every 10000 compounds screened in discovery, approximately 250 compounds will pass through to more rigorous preclinical studies. Eventually, 5 compounds of these 250 will pass to highly regulated clinical trials (Phase1–3). Excluding cancer drugs from the results — which made up fully 31% of all drug programs studied and have overall success rates 5.1% —the overall success rate of all other drugs that enter Phase 1 clinical trials and ultimately reaching FDA approval is 11,9%. The entire process of drug development takes 10 to 15 years and $2.6 billion to bring a drug to market.

Therefore, in order to make this process more efficient hundreds of new data driven startups are working right now from discovery and preclinical phase to clinical phase, trying to optimise every single step of drug development with AI and ML tools.

Let’s see now these startups:

  • Drug discovery phase (screening, chemical synthesis and drug design) startups 🔬

    • Artificial intelligence in drug discovery (part 1): AI tools and startups for primary and secondary screening (2021)

    • Artificial intelligence in compound screening: AI tools and startups for screening hits (high throughput screening in vitro and secondary assays) (2022)

    • Artificial intelligence in drug discovery (part 2): AI tools and startups for planning and execution of chemical synthesis 

    • Artificial intelligence in drug discovery (part 3): AI tools and startups for drug design 

    • Key AI players in the drug discovery market: AI Pharma Startups and their coronavirus initiatives 

    • AI Drug Discovery: Top Investors 

  • AI preclinical phase startups 🐭

    • AI Startups in the Preclinical Phase: AI startups for designing and running preclinical experiments 

    • AI Preclinical Phase: Top Investors 

    • AI Pharma: Best Startups in the Preclinical Phase (2021)

  • AI startups for data aggregation process of the entire AI drug development process 📑📊📈

    • AI Startups for Data Aggregation and Analysis (part 1)

    • AI Startups for Data Aggregation and Analysis (part 2) 

    • AI Pharma: Best Startups for Data Aggregation and Analysis (2021)

  • AI clinical trials startups (design, recruitment and optimisation of clinical trials and digital health: digital therapeutics, wearables and telemedicine) 💉

    • AI Startups for Clinical Trials (part 1)_AI Design, Recruitment and Optimisation of clinical trial 🏥

    • AI Startups for Clinical Trials (part 2)_AI Design, Recruitment and Optimisation of clinical trials 🏥

    • AI Startups for Clinical Trials (part 3a)_Digital health: Digital therapeutics (DTx) 📲📱

    • AI Startups for Clinical Trials (part 3b)_Digital health: Digital therapeutics (DTx) 📲📱

    • AI Startups for Clinical Trials (part 4)_Wearable startups in the mental health and wellness space ⌚️

    • AI Startups for Clinical Trials (part 5)_Telemedicine startups in the mental health and wellness space 

    • Sleep monitoring digital technologies and clinical trials 😴💤🛌🛏

  • AI Drug repurposing Startups 🌀

    • AI Drug Repurposing Startups

    • AI Pharma: Best Startups for Drug Repurposing (2021)

    • Drug repurposing: should I stay or should I go?

    • Should you Date your Ex? Drug Repurposing and AI

    • AI Pharma: Best Startups for Drug Repurposing

  • AI Drug Researching mechanism startups 🕵🏻

    • AI Drug Researching Mechanism Startups (Drug Development)

    • AI Pharma: Best Drug Researching Mechanism Startups (2021)

    • AI Pharma: Best Drug Researching Mechanism Startups

  • Natural Compounds (i.e. Psychedelics) Drug Development Startups 🍄

    • Psychedelics Drug Development: Startups, Clinics, Investors and Non-Profit (part 1)

    • Psychedelics Drug Development: Startups, Clinics, Investors and Non-Profit (part 2)

    • Psychedelics Drug Development: Startups, Clinics, Investors and Non-Profit (part 3)

    • Psychedelic Drug Development (Best 2022)

    • Cannabinoids and Drug Development

  • AI dissemination of biomedical science

    • AI startups transforming dissemination of biomedical science

  • AI and Health

    • Health in the time of artificial intelligence

    • Longevity tips and AI startups

    • Cancer and AI startups


Thank you for reading 💙

And if you liked this post why not share it?

Share

@MetaphysicalCells

#science #health #pharma #AI_drugdiscovery #drugdiscovery #AI #biotechAI  #pharma_AI 

Comment
Share
Share this post
AI Drug Development Startups
marinatalamanou.substack.com

Create your profile

0 subscriptions will be displayed on your profile (edit)

Skip for now

Hi m_al1976@hotmail.com

To post a comment, please re-authenticate.

Check your email

For your security, we need to re-authenticate you.

Click the link we sent to m_al1976@hotmail.com, or click here to sign in.

TopNewCommunity

No posts

© 2022 Marina T Alamanou
Privacy ∙ Terms ∙ Collection notice
Publish on Substack Get the app
Substack is the home for great writing